Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
Ila Tamaskar, Ronald M. Bukowski, Paul J. Elson et al. · Annals of Oncology · 2007
Cited by 147 works. doi:10.1093/annonc/mdm483
Authors
- Ila Tamaskar
- Ronald M. Bukowski
- Paul J. Elson
- Adriana Gabriela Ioachimescu
- L. Wood
- Robert Dreicer
- Tarek M. Mekhail
- J. Garcia
- Brian I. Rini
References
- Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
- In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
- Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains.
- BAY 43-9006 Inhibition of Oncogenic RET Mutants
- Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
- Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- Expression of the ret proto‐oncogene product in human normal and neoplastic tissues of neural crest origin
- Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization